Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study
Purpose Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO. M...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2024-06, Vol.84 (3), p.1072-1080 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1080 |
|---|---|
| container_issue | 3 |
| container_start_page | 1072 |
| container_title | Endocrine |
| container_volume | 84 |
| creator | Wang, Chuyuan Qiao, Jing Liu, Shanshan Piao, Sichen Zhou, Yun Hu, Yuedong Wan, Chao Sun, Yizhou Ning, Hong Chen, Lei Zhang, He Hu, Ruolin Wang, Haoyu Wang, Weiwei Zhao, Lei Mao, Jinyuan Li, Min Teng, Weiping Shan, Zhongyan Li, Yushu |
| description | Purpose
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO.
Methods
We conducted a 5-year prospective controlled cohort clinical trial to determine the effect of selenium on 74 patients with mild-to-moderate GO. Patients received selenium yeast or placebo orally for 6 months and were followed up at 6 months and at 5 years by biochemical examination, ophthalmologist evaluation and QOL questionnaire to assess oculopathy and QOL.
Results
(1) During a follow-up period of 3–6 months, in the selenium group, the symptoms of tearing, grittiness and conjunctival congestion improved (
P
|
| doi_str_mv | 10.1007/s12020-023-03672-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2913443679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3072773894</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-d3e20a3c5ab2f45c3f591fe4dfcff62898f9cd7a6db2f5bef0e746c9ae96c27a3</originalsourceid><addsrcrecordid>eNp9kU1OHDEQha2IKPwkF2CBLGXDxqHabrfH7CJEAAmJRZK15bHLmUbd7cF2I82Oa-R6OQlOhiSIBasq6X31quxHyGEDnxoAdZIbDhwYcMFAdIoz-YbsNVJqBlXfedbvkv2cbwE45516R3bFggO00OyRu6844NTPI-0nWlZIS0JbRpwKjYGO_eBZiWyMHpMtSC-Svcf86-EnjWnZl7i2ZbU5pZZKtkGb6DrFvEZX-nukLk4lxWFAX9tVTIXmMvvNe_I22CHjh6d6QL5_Of92dsmuby6uzj5fMyd4V5gXyMEKJ-2Sh1Y6EaRuArY-uBA6vtCLoJ1XtvNVl0sMgKrtnLaoO8eVFQfkeOtbb7qbMRcz9tnhMNgJ45wN141o2_pvuqIfX6C3cU5Tvc4IUFwpsdBtpfiWcvWROWEw69SPNm1MA-Z3IGYbiKmBmD-BGFmHjp6s5-WI_t_I3wQqILZArtL0A9P_3a_YPgL2LJjo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072773894</pqid></control><display><type>article</type><title>Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wang, Chuyuan ; Qiao, Jing ; Liu, Shanshan ; Piao, Sichen ; Zhou, Yun ; Hu, Yuedong ; Wan, Chao ; Sun, Yizhou ; Ning, Hong ; Chen, Lei ; Zhang, He ; Hu, Ruolin ; Wang, Haoyu ; Wang, Weiwei ; Zhao, Lei ; Mao, Jinyuan ; Li, Min ; Teng, Weiping ; Shan, Zhongyan ; Li, Yushu</creator><creatorcontrib>Wang, Chuyuan ; Qiao, Jing ; Liu, Shanshan ; Piao, Sichen ; Zhou, Yun ; Hu, Yuedong ; Wan, Chao ; Sun, Yizhou ; Ning, Hong ; Chen, Lei ; Zhang, He ; Hu, Ruolin ; Wang, Haoyu ; Wang, Weiwei ; Zhao, Lei ; Mao, Jinyuan ; Li, Min ; Teng, Weiping ; Shan, Zhongyan ; Li, Yushu</creatorcontrib><description>Purpose
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO.
Methods
We conducted a 5-year prospective controlled cohort clinical trial to determine the effect of selenium on 74 patients with mild-to-moderate GO. Patients received selenium yeast or placebo orally for 6 months and were followed up at 6 months and at 5 years by biochemical examination, ophthalmologist evaluation and QOL questionnaire to assess oculopathy and QOL.
Results
(1) During a follow-up period of 3–6 months, in the selenium group, the symptoms of tearing, grittiness and conjunctival congestion improved (
P
< 0.01); clinical activity scores and total GO-QOL scores increased relative to baseline (
P
< 0.01); TRAb was decreased at the 6-month evaluation (
P
= 0.003); and patients treated with selenium had a higher rate of improvement and a lower rate of worsening than patients treated with placebo (
P
< 0.05). (2) Exploratory evaluations at 6 months after drug withdrawal confirmed the earlier results; further changes included alleviation of blurred vision and double vision symptoms in the selenium group (
P
< 0.01). (3) At the 5-year follow-up, compared with baseline, proptosis, clinical activity scores, TRAb level and total GO-QOL scores in both the selenium and placebo groups were significantly improved (
P
< 0.01).
Conclusion
Six months of selenium supplementation may effectively change the early course of mild-to-moderate GO, but this regimen makes no difference in long-term outcomes.</description><identifier>ISSN: 1559-0100</identifier><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-023-03672-5</identifier><identifier>PMID: 38200401</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Clinical trials ; Diabetes ; Endocrinology ; Female ; Follow-Up Studies ; Graves Ophthalmopathy - drug therapy ; Graves' disease ; Humanities and Social Sciences ; Humans ; Internal Medicine ; Longitudinal Studies ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; multidisciplinary ; Original Article ; Patients ; Placebos ; Prospective Studies ; Quality of Life ; Science ; Selenium ; Selenium - therapeutic use ; Severity of Illness Index ; Treatment Outcome ; Vision</subject><ispartof>Endocrine, 2024-06, Vol.84 (3), p.1072-1080</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-d3e20a3c5ab2f45c3f591fe4dfcff62898f9cd7a6db2f5bef0e746c9ae96c27a3</cites><orcidid>0000-0002-7168-9920 ; 0000-0002-3893-105X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-023-03672-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-023-03672-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38200401$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Chuyuan</creatorcontrib><creatorcontrib>Qiao, Jing</creatorcontrib><creatorcontrib>Liu, Shanshan</creatorcontrib><creatorcontrib>Piao, Sichen</creatorcontrib><creatorcontrib>Zhou, Yun</creatorcontrib><creatorcontrib>Hu, Yuedong</creatorcontrib><creatorcontrib>Wan, Chao</creatorcontrib><creatorcontrib>Sun, Yizhou</creatorcontrib><creatorcontrib>Ning, Hong</creatorcontrib><creatorcontrib>Chen, Lei</creatorcontrib><creatorcontrib>Zhang, He</creatorcontrib><creatorcontrib>Hu, Ruolin</creatorcontrib><creatorcontrib>Wang, Haoyu</creatorcontrib><creatorcontrib>Wang, Weiwei</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Mao, Jinyuan</creatorcontrib><creatorcontrib>Li, Min</creatorcontrib><creatorcontrib>Teng, Weiping</creatorcontrib><creatorcontrib>Shan, Zhongyan</creatorcontrib><creatorcontrib>Li, Yushu</creatorcontrib><title>Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO.
Methods
We conducted a 5-year prospective controlled cohort clinical trial to determine the effect of selenium on 74 patients with mild-to-moderate GO. Patients received selenium yeast or placebo orally for 6 months and were followed up at 6 months and at 5 years by biochemical examination, ophthalmologist evaluation and QOL questionnaire to assess oculopathy and QOL.
Results
(1) During a follow-up period of 3–6 months, in the selenium group, the symptoms of tearing, grittiness and conjunctival congestion improved (
P
< 0.01); clinical activity scores and total GO-QOL scores increased relative to baseline (
P
< 0.01); TRAb was decreased at the 6-month evaluation (
P
= 0.003); and patients treated with selenium had a higher rate of improvement and a lower rate of worsening than patients treated with placebo (
P
< 0.05). (2) Exploratory evaluations at 6 months after drug withdrawal confirmed the earlier results; further changes included alleviation of blurred vision and double vision symptoms in the selenium group (
P
< 0.01). (3) At the 5-year follow-up, compared with baseline, proptosis, clinical activity scores, TRAb level and total GO-QOL scores in both the selenium and placebo groups were significantly improved (
P
< 0.01).
Conclusion
Six months of selenium supplementation may effectively change the early course of mild-to-moderate GO, but this regimen makes no difference in long-term outcomes.</description><subject>Adult</subject><subject>Aged</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graves Ophthalmopathy - drug therapy</subject><subject>Graves' disease</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Original Article</subject><subject>Patients</subject><subject>Placebos</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Science</subject><subject>Selenium</subject><subject>Selenium - therapeutic use</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Vision</subject><issn>1559-0100</issn><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1OHDEQha2IKPwkF2CBLGXDxqHabrfH7CJEAAmJRZK15bHLmUbd7cF2I82Oa-R6OQlOhiSIBasq6X31quxHyGEDnxoAdZIbDhwYcMFAdIoz-YbsNVJqBlXfedbvkv2cbwE45516R3bFggO00OyRu6844NTPI-0nWlZIS0JbRpwKjYGO_eBZiWyMHpMtSC-Svcf86-EnjWnZl7i2ZbU5pZZKtkGb6DrFvEZX-nukLk4lxWFAX9tVTIXmMvvNe_I22CHjh6d6QL5_Of92dsmuby6uzj5fMyd4V5gXyMEKJ-2Sh1Y6EaRuArY-uBA6vtCLoJ1XtvNVl0sMgKrtnLaoO8eVFQfkeOtbb7qbMRcz9tnhMNgJ45wN141o2_pvuqIfX6C3cU5Tvc4IUFwpsdBtpfiWcvWROWEw69SPNm1MA-Z3IGYbiKmBmD-BGFmHjp6s5-WI_t_I3wQqILZArtL0A9P_3a_YPgL2LJjo</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Wang, Chuyuan</creator><creator>Qiao, Jing</creator><creator>Liu, Shanshan</creator><creator>Piao, Sichen</creator><creator>Zhou, Yun</creator><creator>Hu, Yuedong</creator><creator>Wan, Chao</creator><creator>Sun, Yizhou</creator><creator>Ning, Hong</creator><creator>Chen, Lei</creator><creator>Zhang, He</creator><creator>Hu, Ruolin</creator><creator>Wang, Haoyu</creator><creator>Wang, Weiwei</creator><creator>Zhao, Lei</creator><creator>Mao, Jinyuan</creator><creator>Li, Min</creator><creator>Teng, Weiping</creator><creator>Shan, Zhongyan</creator><creator>Li, Yushu</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7168-9920</orcidid><orcidid>https://orcid.org/0000-0002-3893-105X</orcidid></search><sort><creationdate>20240601</creationdate><title>Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study</title><author>Wang, Chuyuan ; Qiao, Jing ; Liu, Shanshan ; Piao, Sichen ; Zhou, Yun ; Hu, Yuedong ; Wan, Chao ; Sun, Yizhou ; Ning, Hong ; Chen, Lei ; Zhang, He ; Hu, Ruolin ; Wang, Haoyu ; Wang, Weiwei ; Zhao, Lei ; Mao, Jinyuan ; Li, Min ; Teng, Weiping ; Shan, Zhongyan ; Li, Yushu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-d3e20a3c5ab2f45c3f591fe4dfcff62898f9cd7a6db2f5bef0e746c9ae96c27a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graves Ophthalmopathy - drug therapy</topic><topic>Graves' disease</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Original Article</topic><topic>Patients</topic><topic>Placebos</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Science</topic><topic>Selenium</topic><topic>Selenium - therapeutic use</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Vision</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Chuyuan</creatorcontrib><creatorcontrib>Qiao, Jing</creatorcontrib><creatorcontrib>Liu, Shanshan</creatorcontrib><creatorcontrib>Piao, Sichen</creatorcontrib><creatorcontrib>Zhou, Yun</creatorcontrib><creatorcontrib>Hu, Yuedong</creatorcontrib><creatorcontrib>Wan, Chao</creatorcontrib><creatorcontrib>Sun, Yizhou</creatorcontrib><creatorcontrib>Ning, Hong</creatorcontrib><creatorcontrib>Chen, Lei</creatorcontrib><creatorcontrib>Zhang, He</creatorcontrib><creatorcontrib>Hu, Ruolin</creatorcontrib><creatorcontrib>Wang, Haoyu</creatorcontrib><creatorcontrib>Wang, Weiwei</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Mao, Jinyuan</creatorcontrib><creatorcontrib>Li, Min</creatorcontrib><creatorcontrib>Teng, Weiping</creatorcontrib><creatorcontrib>Shan, Zhongyan</creatorcontrib><creatorcontrib>Li, Yushu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Chuyuan</au><au>Qiao, Jing</au><au>Liu, Shanshan</au><au>Piao, Sichen</au><au>Zhou, Yun</au><au>Hu, Yuedong</au><au>Wan, Chao</au><au>Sun, Yizhou</au><au>Ning, Hong</au><au>Chen, Lei</au><au>Zhang, He</au><au>Hu, Ruolin</au><au>Wang, Haoyu</au><au>Wang, Weiwei</au><au>Zhao, Lei</au><au>Mao, Jinyuan</au><au>Li, Min</au><au>Teng, Weiping</au><au>Shan, Zhongyan</au><au>Li, Yushu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>84</volume><issue>3</issue><spage>1072</spage><epage>1080</epage><pages>1072-1080</pages><issn>1559-0100</issn><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO.
Methods
We conducted a 5-year prospective controlled cohort clinical trial to determine the effect of selenium on 74 patients with mild-to-moderate GO. Patients received selenium yeast or placebo orally for 6 months and were followed up at 6 months and at 5 years by biochemical examination, ophthalmologist evaluation and QOL questionnaire to assess oculopathy and QOL.
Results
(1) During a follow-up period of 3–6 months, in the selenium group, the symptoms of tearing, grittiness and conjunctival congestion improved (
P
< 0.01); clinical activity scores and total GO-QOL scores increased relative to baseline (
P
< 0.01); TRAb was decreased at the 6-month evaluation (
P
= 0.003); and patients treated with selenium had a higher rate of improvement and a lower rate of worsening than patients treated with placebo (
P
< 0.05). (2) Exploratory evaluations at 6 months after drug withdrawal confirmed the earlier results; further changes included alleviation of blurred vision and double vision symptoms in the selenium group (
P
< 0.01). (3) At the 5-year follow-up, compared with baseline, proptosis, clinical activity scores, TRAb level and total GO-QOL scores in both the selenium and placebo groups were significantly improved (
P
< 0.01).
Conclusion
Six months of selenium supplementation may effectively change the early course of mild-to-moderate GO, but this regimen makes no difference in long-term outcomes.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38200401</pmid><doi>10.1007/s12020-023-03672-5</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7168-9920</orcidid><orcidid>https://orcid.org/0000-0002-3893-105X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1559-0100 |
| ispartof | Endocrine, 2024-06, Vol.84 (3), p.1072-1080 |
| issn | 1559-0100 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2913443679 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Clinical trials Diabetes Endocrinology Female Follow-Up Studies Graves Ophthalmopathy - drug therapy Graves' disease Humanities and Social Sciences Humans Internal Medicine Longitudinal Studies Male Medicine Medicine & Public Health Middle Aged multidisciplinary Original Article Patients Placebos Prospective Studies Quality of Life Science Selenium Selenium - therapeutic use Severity of Illness Index Treatment Outcome Vision |
| title | Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A47%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selenium%20in%20the%20treatment%20of%20mild-to-moderate%20Graves%E2%80%99%20orbitopathy:%20a%205-year%20prospective%20controlled%20cohort%20study&rft.jtitle=Endocrine&rft.au=Wang,%20Chuyuan&rft.date=2024-06-01&rft.volume=84&rft.issue=3&rft.spage=1072&rft.epage=1080&rft.pages=1072-1080&rft.issn=1559-0100&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-023-03672-5&rft_dat=%3Cproquest_cross%3E3072773894%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3072773894&rft_id=info:pmid/38200401&rfr_iscdi=true |